


AZ-1355

Cat. No.:	HY-101692
CAS No.:	75451-07-9
Molecular Formula:	C ₁₇ H ₁₇ NO ₄
Molecular Weight:	299.32
Target:	Prostaglandin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	AZ-1355 is an effective lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I ₂ /thromboxane A ₂ ratio in vitro.	
IC ₅₀ & Target	TXA ₂ /TP	Prostaglandin I ₂
In Vivo	<p>AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rat. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	

PROTOCOL

Animal Administration ^[1]	<p>Mice^[1] Male mice, strain ddY, 6 weeks old are used in the assay. The mice are fasted overnight and then Triton WR-1399 (500 mg/kg) is intravenously injected. Immediately and 8 h after the injection, AZ-1366 or clofibrate (both 150 mg/kg, each) are given to the mice orally. The control mice receive the vehicle, 1% aqueous methycellulose. The mice are maintained for 24 h on drinking water only and then the blood is withdrawn from the heart.</p> <p>Rats^[1] Male rats, strain Sprague-Dawley, 6 weeks old are used in the assay. A total of 56 rats are randomly assigned to 2 equal groups. One group is fed the CE-2 diet and the other the high fat diet. Each group is further subdivided into 4 equal groups (n=7). The rats in the first subgroup receives the vehicle, 5% aqueous gum arabic solution, orally (1 ml 100 g body weight). The second sub-group receives clofibrate (100 mg/kg daily), and the third and the fourth receive AZ-1355 in daily doses of 50 and 100 mg/kg, respectively. The drug is administered once a day for 4 consecutive weeks. Body weights are monitored daily. There is no difference in weight gains between the treated and corresponding control groups.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
--------------------------------------	--

REFERENCES

[1]. Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. *Atherosclerosis*. 1981 Nov-Dec;40(3-4):263-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA